Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics: "noninferiority" is sufficient for initial implementation.

Clinical pharmacology and therapeutics - 1 Mar 2011

Altman R B

Abstract excerpt

Recent clinical annotation of a whole-genome sequence suggests that pharmacogenomics (PGx) may be ready for clinical implementation now. This conclusion rests on the recognition that PGx has greatly mitigated risks as compared with using genomics for assessment of disease risk. Failure to recognize these differences can produce unrealistic cost-benefit scenarios and impractical standards of evidence. In many...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Drug-Related Side Effects and Adverse Reactions
Share to Genome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmaceutical Preparations

Share to Pharmacogenetics

Share to Practice Guidelines as Topic

Share to Practice Patterns, Physicians'

Source

Identifiers

PMID: 21326263
DOI: 10.1038/clpt.2010.310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics: "noninferiority" is sufficient for initial implementation.PMID 21326263Read ↗

Clinical and moral challenges of pharmacogenomics.Semantic proximity Read ↗

Ethical, social and legal issues in pharmacogenomicsSemantic proximity Read ↗

Requirements for comprehensive pharmacogenetic genotyping platforms.Semantic proximity Read ↗

Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.Semantic proximity Read ↗

Ethical considerations in clinical pharmacogenomics researchSemantic proximity Read ↗

Real-world Clinical Effectiveness, Regulatory Transparency and Payer Coverage: Three Ingredients for Translating Pharmacogenomics into Clinical PracticeSemantic proximity Read ↗

Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.Semantic proximity Read ↗

Pharmacogenetic Testing: A Tool for Personalized Drug Therapy OptimizationSemantic proximity Read ↗

Pharmacogenomics: playing the odds.Semantic proximity Read ↗

Proprietary Algorithms for Polygenic Risk: Protecting Scientific Innovation or Hiding the Lack of It?Semantic proximity Read ↗

Ethical and legal implications of pharmacogenomics.Semantic proximity Read ↗

Why pharmacogenomics? Why now?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.